Wall Street analysts expect that Mediwound Ltd (NASDAQ:MDWD) will post sales of $2.67 million for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Mediwound’s earnings, with the highest sales estimate coming in at $4.10 million and the lowest estimate coming in at $1.20 million. Mediwound posted sales of $860,000.00 during the same quarter last year, which indicates a positive year over year growth rate of 210.5%. The firm is expected to issue its next earnings report on Tuesday, November 12th.
According to Zacks, analysts expect that Mediwound will report full year sales of $17.00 million for the current year, with estimates ranging from $8.80 million to $26.50 million. For the next fiscal year, analysts anticipate that the company will post sales of $12.12 million, with estimates ranging from $5.89 million to $18.20 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Mediwound.
Mediwound (NASDAQ:MDWD) last posted its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.03. The company had revenue of $20.75 million during the quarter, compared to the consensus estimate of $7.03 million. Mediwound had a net margin of 70.54% and a negative return on equity of 156.56%.
A number of institutional investors have recently added to or reduced their stakes in MDWD. Delek Group Ltd. purchased a new position in Mediwound during the first quarter worth about $141,000. Marshall Wace LLP purchased a new position in Mediwound during the first quarter worth about $93,000. ARK Investment Management LLC purchased a new position in Mediwound during the second quarter worth about $325,000. Oppenheimer & Co. Inc. boosted its holdings in Mediwound by 33.5% during the second quarter. Oppenheimer & Co. Inc. now owns 43,800 shares of the biopharmaceutical company’s stock worth $148,000 after purchasing an additional 11,000 shares during the last quarter. Finally, Sargent Investment Group LLC boosted its holdings in Mediwound by 114.8% during the second quarter. Sargent Investment Group LLC now owns 29,000 shares of the biopharmaceutical company’s stock worth $98,000 after purchasing an additional 15,500 shares during the last quarter. Institutional investors and hedge funds own 28.75% of the company’s stock.
Shares of NASDAQ:MDWD traded down $0.01 during midday trading on Friday, hitting $2.98. 22,612 shares of the company’s stock were exchanged, compared to its average volume of 28,180. The company has a debt-to-equity ratio of 0.11, a current ratio of 4.13 and a quick ratio of 3.99. The stock has a 50 day moving average price of $3.13 and a 200-day moving average price of $3.79. The company has a market cap of $79.91 million, a PE ratio of -6.08 and a beta of 0.48. Mediwound has a 12 month low of $2.55 and a 12 month high of $6.19.
Mediwound Company Profile
MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina.
Recommended Story: How to start trading in the forex market?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.